Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1997-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM.82.8.4178-2PMID 9253367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel expression of functional luteinizing hormone/chorionic gonadotropin receptors in cultured glial cells from neonatal rat brains.

  1997cited by this paper
• Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

  1997cited by this paper
• Neurons from fetal rat brains contain functional luteinizing hormone/chorionic gonadotropin receptors.

  1997cited by this paper
• Immunohistochemical localization of gonadotropin and gonadal steroid receptors in human pineal glands.

  1997cited by this paper
• cis-Acting Elements and trans-Acting Proteins in the Transcriptional Inhibition of Gonadotropin-releasing Hormone Gene by Human Chorionic Gonadotropin in Immortalized Hypothalamic GT1–7 Neurons*

  1997cited by this paper
• Seasonal variation of gonadotropins and gonadal steroids receptors in the human pineal gland.

  1997cited by this paper
• Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.

  1996cited by this paper
• Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.

  1996cited by this paper
• Human chorionic gonadotropin down-regulates the expression of gonadotropin-releasing hormone receptor gene in GT1-7 neurons.

  1996cited by this paper
• Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.

  1996cited by this paper
• Immunohistochemical localization of heat shock proteins HSP70 and HSP90 in the human endometrium: correlation with sex steroid receptors and Ki-67 antigen expression.

  1995cited by this paper
• Signaling and transacting factors in the transcriptional inhibition of gonadotropin releasing hormone gene by human chorionic gonadotropin in immortalized hypothalamic GT1-7 neurons.

  1995cited by this paper
• Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats.

  1995cited by this paper
• Administration of human chorionic gonadotropin affects sleep-wake phases and other associated behaviors in cycling female rats.

  1994cited by this paper
• Novel presence of luteinizing hormone/human chorionic gonadotropin (hCG) receptors and the down-regulating action of hCG on gonadotropin-releasing hormone gene expression in immortalized hypothalamic GT1-7 neurons.

  1994cited by this paper
• Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.

  1994cited by this paper
• Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain.

  1993cited by this paper
• Cabergoline in the long-term therapy of hyperprolactinemic disorders.

  1992cited by this paper
• Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.

  1992cited by this paper
• Clinical management of prolactinomas: A ten-year experience

  1992cited by this paper
• The role of ligand in estrogen receptor regulation of gene expression.

  1991cited by this paper
• Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine‐resistant prolactinomas

  1991cited by this paper
• Should dopamine agonist treatment for prolactinomas be life‐long?

  1991cited by this paper
• In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.

  1990cited by this paper
• In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205-502.

  1988cited by this paper
• The pineal gland: anatomy, physiology, and clinical significance.

  1985cited by this paper

• Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas

  2023cites this paper
• Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia

  2016cites this paper
• Pharmacological Therapy for Acromegaly

  2012cites this paper
• Contemporary management of prolactinomas.

  2004cites this paper
• Pharmacological therapy for acromegaly: a critical review.

  2004cites this paper
• Influence of Age on the Clinical Presentation of Prolactinomas in Male Patients

  1999cites this paper
• Cabergoline in prolactinomas

  1999cites this paper
• Dopamine agonist therapy in hyperprolactinemia.

  1999cites this paper
• New Medical Treatment for Acromegaly

  1999cites this paper
• Clinical management of prolactinomas.

  1999cites this paper